breast-cancer

New lab platform mimics how breast cancer cells choose which organs to invade

Researchers have developed an ex vivo invasion assay that uses real mouse organ tissue — lungs, liver, and intestine — stripped of cells but with the extracellular matrix (ECM) intact, then sliced and loaded into microfluidic channels. Cancer cells can be added and their invasion tracked under a microscope.

When they tested breast cancer cell lines of known invasive behavior, non-invasive cells (MCF7) failed to penetrate any organ scaffold, while aggressive cells (MDA-MB-231) preferentially invaded lung and liver but not intestine — exactly mirroring the clinical pattern of breast cancer metastasis. Invasion rates matched those measured in live-animal studies.

This tool sits between overly simplified lab dishes and expensive, hard-to-control animal experiments. It could accelerate the testing of anti-metastasis drugs and help explain why certain cancers spread preferentially to specific organs.

Key Findings

Organ-specific ECM scaffolds preserve native matrix architecture and mechanical properties after decellularization
Aggressive MDA-MB-231 breast cancer cells preferentially invaded lung and liver ECM but not intestinal scaffolds
Non-invasive MCF7 cells failed to infiltrate any organ scaffold
Quantitative invasion rates matched in vivo intravital microscopy benchmarks
Platform is scalable and compatible with standard fluorescence microscopy

Implications

A validated ex vivo organ invasion model could serve as a cost-effective screening tool for anti-metastatic compounds, reducing animal use. It also provides a mechanistic platform to study ECM composition's role in driving organ-specific metastatic tropism — a long-standing question in cancer biology.

Caveats

Preprint — not peer reviewed. ECM scaffolds are derived from mouse organs, which may not fully recapitulate human tissue architecture. Study uses established cell lines rather than patient-derived cells. Does not model vascular, lymphatic, or immune components of metastasis.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.